Title: AMEND S e n ate Bill No. 436* House Bill No. 1198
Official Title: AMEND S e n ate Bill No. 436* House Bill No. 1198
Number of Sections: 8
Source: versions - Amendment SA0236
Media Type: application/pdf
Strikethrough Detection: 2 sections found

================================================================================

Section 1:
Senate Commerce and Labor 1
Amendment No. 1 to SB0436
Bailey
Signature of Sponsor
by deleting all language after the caption and substituting:
WHEREAS, the legislature finds that increasing access to biosimilar medicines has the
potential to significantly reduce prescription drug costs; and
WHEREAS, biosimilar medicines are approved according to the same federal Food and
Drug Administration (FDA) standards of pharmaceutical quality, safety, and efficacy as the
FDA's reference medicines; and
WHEREAS, it is the intent of the legislature to eliminate barriers impeding access to
biosimilar medicines and the savings biosimilar medicines can provide; now, therefore,
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:

Section 2:
SECTION 1. Tennessee Code Annotated, Section 4-3-1013(e), is amended by adding
the language "or biosimilars, as that term is defined in § 56-7-3501" at the end of the
subsection.

Section 3:
SECTION 2. Tennessee Code Annotated, Section 56-7-3501, is amended by adding
the following as a new subdivision:
( ) "Biosimilar" means a biological product that is licensed under 42 U.S.C. §
262(k) and that is not listed as "discontinued" in the federal food and drug
administration's database of licensed biological products, also known as the "Purple
Book";

Section 4:
SECTION 3. Tennessee Code Annotated, Section 56-7-3502(f)(1), is amended by
deleting the subdivision and substituting:
SA0236
004872
- 1 -
(1) A health carrier, health benefit plan, or utilization review organization from
requiring a patient to try an AB-rated generic equivalent product, interchangeable
biological product, or biosimilar product prior to providing coverage for the equivalent
branded prescription drug;

Section 5:
SECTION 4. Tennessee Code Annotated, Section 71-5-103, is amended by adding the
following as a new subdivision:
( ) "Biosimilar" means a biological product that is licensed under 42 U.S.C. §
262(k) and that is not listed as "discontinued" in the federal food and drug
administration's database of licensed biological products, also known as the "Purple
Book";

Section 6:
SECTION 5. Tennessee Code Annotated, Section 71-5-198(c), is amended by adding
the language "or biosimilars" at the end of the subsection.

Section 7:
SECTION 6. Tennessee Code Annotated, Section 71-5-2404(a), is amended by
deleting the language "including, but not limited to, efficacy, the use of generic drugs and
therapeutic equivalent drugs, and cost information related to each drug" and substituting
"including efficacy; the use of generic drugs, biosimilars, as that term is defined in § 71-5-103,
and therapeutic equivalent drugs; and cost information related to each drug".

Section 8:
SECTION 7. This act takes effect upon becoming a law, the public welfare requiring it.
- 2 - 004872
[DELETED:  a HWSS(S]
[DELETED:  -0((SSS]


================================================================================

Raw Text:
Senate Commerce and Labor 1
Amendment No. 1 to SB0436
Bailey
Signature of Sponsor
AMEND S e n ate Bill No. 436* House Bill No. 1198
by deleting all language after the caption and substituting:
WHEREAS, the legislature finds that increasing access to biosimilar medicines has the
potential to significantly reduce prescription drug costs; and
WHEREAS, biosimilar medicines are approved according to the same federal Food and
Drug Administration (FDA) standards of pharmaceutical quality, safety, and efficacy as the
FDA's reference medicines; and
WHEREAS, it is the intent of the legislature to eliminate barriers impeding access to
biosimilar medicines and the savings biosimilar medicines can provide; now, therefore,
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF TENNESSEE:
SECTION 1. Tennessee Code Annotated, Section 4-3-1013(e), is amended by adding
the language "or biosimilars, as that term is defined in § 56-7-3501" at the end of the
subsection.
SECTION 2. Tennessee Code Annotated, Section 56-7-3501, is amended by adding
the following as a new subdivision:
( ) "Biosimilar" means a biological product that is licensed under 42 U.S.C. §
262(k) and that is not listed as "discontinued" in the federal food and drug
administration's database of licensed biological products, also known as the "Purple
Book";
SECTION 3. Tennessee Code Annotated, Section 56-7-3502(f)(1), is amended by
deleting the subdivision and substituting:
SA0236
004872
- 1 -

(1) A health carrier, health benefit plan, or utilization review organization from
requiring a patient to try an AB-rated generic equivalent product, interchangeable
biological product, or biosimilar product prior to providing coverage for the equivalent
branded prescription drug;
SECTION 4. Tennessee Code Annotated, Section 71-5-103, is amended by adding the
following as a new subdivision:
( ) "Biosimilar" means a biological product that is licensed under 42 U.S.C. §
262(k) and that is not listed as "discontinued" in the federal food and drug
administration's database of licensed biological products, also known as the "Purple
Book";
SECTION 5. Tennessee Code Annotated, Section 71-5-198(c), is amended by adding
the language "or biosimilars" at the end of the subsection.
SECTION 6. Tennessee Code Annotated, Section 71-5-2404(a), is amended by
deleting the language "including, but not limited to, efficacy, the use of generic drugs and
therapeutic equivalent drugs, and cost information related to each drug" and substituting
"including efficacy; the use of generic drugs, biosimilars, as that term is defined in § 71-5-103,
and therapeutic equivalent drugs; and cost information related to each drug".
SECTION 7. This act takes effect upon becoming a law, the public welfare requiring it.
- 2 - 004872

[DELETED:  a HWSS(S]
[DELETED:  -0((SSS]